Apple Turns iPhone into Ultimate Tracking Tool by Offering Banking Services – AppleID to Become National Digital ID?

Who needs CBDCs or a National Digital ID program to track every financial transaction you make, when Apple has already beat everyone to the punch with their AppleID that now can be linked to your bank account as well? Yesterday, Apple announced that they are now offering attractive rates on savings accounts through their Apple Wallet, as they team up with banking giant Goldman Sachs. With Elon Musk and others racing to create the first "do everything" app that can track pretty much everything one does in life, Apple just beat everyone to the punch by effectively making the iPhone, which is already in the hands of over 120 million people in the U.S., and over 1 billion worldwide, a device that can now pretty much link everything you do to your AppleID. This is a brilliant move by Goldman Sachs, which like all U.S. banks right now, is seeing a mass exodus of deposits since the banking crisis started last month. In their first quarter report today, Goldman Sachs CEO David Solomon admitted that this partnership with Apple will increase bank deposits for their troubled bank. Pam Martens of Wall Street on Parade also covered this new venture today, reminding everyone how Goldman Sachs is part of the criminal banking cartel with their history of "dubious dealings" going all the way back to the Wall Street financial crash of 1929.

Investment Report Reveals Medical Cures not Profitable for Big Pharma – Sick People Needed to Sustain Drug Sales

A report that made its way through the corporate sponsored "mainstream" media last week demonstrated what those of us in the alternative health media have been publishing for years: Pharmaceutical products which actually cure people are not invested in, simply because it is not a sustainable market when people are cured and no longer need Big Pharma's drugs. Investors cannot afford to invest in such products. Originally reported on CNBC.com, an April 10 report by Goldman Sachs analysts entitled "The Genome Revolution" addressed the question: "Is curing patients a sustainable business model?"